Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Long-term outcomes following Cionni Ring bag fixation and in-the-bag IOL implantation: prospective study

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Cataract Complications & Special Cases

Venue: Poster Village: Pod 1

First Author: : S.Vasavada INDIA

Co Author(s): :    S. Srivastava   A. Vasavada   V. Vasavada                 

Abstract Details

Purpose:

To report the longterm outcomes following Cionni modified capsule tension ring (CTR) fixation of the capsular bag and in-the-bag IOL implantation

Setting:

Iladevi Cataract & Research Centre, Raghudeep Eye Hospital, Ahmedabad, India

Methods:

Prospective, observational case series. The study population comprised 30 eyes with subluxated lenses that underwent lens extraction, capsular bag fixation with Cionni CTR, and in-the-bag IOL implantation. All eyes completed minimum 7 years follow-up. Main outcome measures were longterm postoperative best-corrected visual acuity (BCVA), IOL centration, and complications.

Results:

Mean age:29.4±16.6 yrs.Mean extent of subluxation 6.1±1.0 clock hours.Marfan’s Syndrome was the most common identifiable cause of subluxation in 65%.Anterior vitrectomy performed in 2 eyes.22eyes had a Single-element Cionni ring and 8 eyes Double element ring for bag fixation.Mean follow-up:90.1 ± 4.9 months.Mean preop BCVA:0.66±0.22 logMAR.Mean postop BCVA at final follow-up:0.33 ± 0.21 logMAR(P<.001).BCVA improved in 25 eyes(85%).IOL decentration noted in 4 eyes(13.3%),requiring repositioning in 3 eyes.9 eyes(30%) required Nd:YAG capsulotomy for PCO.Other complications included cystoid macular edema in 1(3.3%),posterior synechiae in 2 (6.6%),retinal detachment in 2(6.6%) eyes

Conclusions:

In-the-bag implantation of a Cionni CTR with IOL appears to be a safe option in eyes with subluxated cataract, ensuring a stable IOL with acceptable rate of complications in the longterm

Financial Disclosure:

None

Back to previous